Optimizing Bispecific Antibody Administration With EHR and Technology Solutions

ACIP delayed the vote on the hepatitis B vaccine schedule amid ongoing controversy and misinformation surrounding vaccine safety and infant immunization.

Experts discuss the clinical and economic burden of idiopathic pulmonary fibrosis (IPF), emerging clinical data, and strategies to improve patient outcomes.

Guideline-recommended HF therapies do not improve major outcomes in Chagas disease, though sacubitril/valsartan improved NT-proBNP levels, new data show.

Lead CML researcher discusses the evolution of a groundbreaking treatment and its effect on patient survival.

The authors sought to understand the differential impact of payer-led community-based care management approaches on stakeholder-oriented outcomes for publicly insured adults with multiple chronic conditions.

The combination of olomorasib and pembrolizumab to treat KRAS G12C-mutant advanced NSCLC showed promising antitumor activity.